CLLS

Cellectis S.A.

2.89 USD

Last updated Dec 6, 17:43 UTC

Yesterday HIGH

$2.92

Yesterday LOW

$2.8

52w HIGH

$4.04

52w LOW

$0.96

EPS

-0.36

PE

-8.03

Next Earnings

Mar 6, 2024

Overview News Government Trades

Cellectis S.A. stock is up 4.71% since 30 days ago. The next earnings date is Mar 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 44.44% of the previous 8 December’s closed higher than November.

Cellectis S.A. develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

Paris 13, France

Website

cellectis.com

Benzinga Newsdesk

Thu Oct 12, 2023

Cellectis And Imagine Institute Publish A Proof-Of-Concept Study Of A Gene Surgery Candidate To Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1

Preclinical results demonstrated that:The PIK3CD gene can be efficiently corrected by TALEN®-mediated gene insertion of the functional PIK3CD DNA sequence vectorized by AAV, in healthy donor and APDS1 patient
Benzinga Insights

Tue Oct 3, 2023

Stocks That Hit 52-Week Lows On Tuesday

On Tuesday, 647 companies set new 52-week lows.
Benzinga Insights

Mon Oct 2, 2023

Stocks That Hit 52-Week Lows On Monday

On Monday, 369 companies set new 52-week lows.
Benzinga Newsdesk

Wed Sep 27, 2023

Cellectis To Present Pre-Clinical Data On Multi-Armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer At The Society For Immunotherapy Of Cancer 38th Annual Meeting

Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that pre-clinical data on
richadhand@benzinga.com

Tue Aug 8, 2023

Oppenheimer Reiterates Outperform on Cellectis, Maintains $11 Price Target

Oppenheimer analyst Hartaj Singh reiterates Cellectis (NASDAQ:CLLS) with a Outperform and maintains $11 price target.
Benzinga Newsdesk

Mon Aug 7, 2023

Cellectis Q2 Adj $(0.15) Beats $(0.45) Estimate, Sales $2.00M Miss $4.48M Estimate

Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.45) by 66.67 percent. This is a 58.33 percent increase over losses of $(0.36) per share from the
richadhand@benzinga.com

Mon Aug 7, 2023

JMP Securities Reiterates Market Outperform on Cellectis, Maintains $6 Price Target

JMP Securities analyst Silvan Tuerkcan reiterates Cellectis (NASDAQ:CLLS) with a Market Outperform and maintains $6 price target.
vinayak@benzinga.com

Thu Aug 3, 2023

Cellectis Q2 Adj EPS $(0.15) Beats $(0.45) Estimate, Sales $2.00M Miss $4.48M Estimate

Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.45) by 66.67 percent. This is a 58.33 percent increase over losses of $(0.36) per share from the
Benzinga Insights

Thu Aug 3, 2023

Earnings Scheduled For August 3, 2023

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.
Happy Mohamed

Fri Jun 9, 2023

Cellectis Presents Updated Clinical And Translational Data On BALLI-01 At The European Hematology Association 2023

Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, presented today updated clinical